|
Community pharmacists are well-placed within the healthcare system to provide pharmacogenomics services
|
29 (18.0)
|
31 (19.3)
|
29 (18.0)
|
31 (19.3)
|
40 (24.8)
|
|
Pharmacogenomics testing services is feasible in community pharmacy setting
|
34 (21.1)
|
36 (22.4)
|
38 (23.6)
|
40 (24.8)
|
12 (7.5)
|
|
Community pharmacists have the expertise to interpret and adjust medication doses based on patient’s pharmacogenomics results
|
36 (22.4)
|
50 (31.1)
|
42 (26.1)
|
12 (7.5)
|
20 (12.4)
|
|
Community pharmacists need training in pharmacogenomics
|
91 (56.5)
|
50 (31.1)
|
14 (8.7)
|
2 (1.2)
|
1 (0.6)
|
|
Physicians and community pharmacists should collaborate to offer pharmacogenomics testing
|
103 (64.0)
|
49 (30.4)
|
6 (3.7)
|
2 (1.2)
| |
|
Pharmacogenomics testing will prevent your patient from taking the inappropriate medicine or the wrong dose
|
97 (60.2)
|
49 (30.4)
|
11 (6.8)
|
2 (1.2)
|
1 (0.6)
|
|
Incorporation of pharmacogenetic screening into medication therapy management will optimize pharmacotherapy
|
65 (40.4)
|
75 (46.6)
|
15 (9.3)
|
3 (1.9)
| |
|
Pharmacogenomics testing will become a routine in clinical practice in the future
|
54 (33.5)
|
43 (26.7)
|
31 (19.3)
|
26 (16.1)
|
5 (3.1)
|
|
Pharmacogenomics-guided treatment is cost-effective
|
40 (24.8)
|
68 (42.2)
|
29 (18.0)
|
7 (4.3)
|
11 (6.8)
|
|
Barriers to implementation of pharmacogenomics services
|
|
Lack of knowledge
|
86 (53.4)
|
58 (36.0)
|
8 (5.0)
|
2 (1.2)
|
2 (1.2)
|
|
Lack of reimbursement
|
71 (44.1)
|
60 (37.3)
|
16 (9.9)
|
5 (3.1)
|
2 (1.2)
|
|
Lack of time
|
63 (39.1)
|
53 (32.9)
|
25 (15.5)
|
10 (6.2)
|
3 (1.9)
|
|
Lack of guidelines
|
82 (50.9)
|
59 (36.6)
|
8 (5.0)
|
5 (3.1)
|
1 (0.6)
|
|
Ethical considerations regarding ownership of genetic data
|
77 (47.8)
|
44 (27.3)
|
28 (17.4)
|
2 (1.2)
|
3 (1.9)
|
|
Resistance from other healthcare professionals
|
74 (46.0)
|
52 (32.3)
|
24 (14.9)
|
4 (2.5)
|
1 (0.6)
|
|
Lack of acceptance by patients
|
78 (48.4)
|
40 (24.8)
|
22 (13.7)
|
8 (5.0)
|
7 (4.3)
|
